XENE Live-Signale | Maximieren Sie Profite mit Getagraph.com

VERKAUFEN 109816 min ago

@ $49.08

Ausgestellt: 13 Feb 2024 @ 17:05

Rendite: -12.93%

Vorheriges Signal: Feb 12 - 21:25

Vorheriges Signal: Kaufen

Rendite: -0.13 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:00):

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada...

Stats
Tagesvolumen	592 795
Durchschnittsvolumen	359 750
Marktkapitalisierung	3.22B
EPS	$0 ( 2024-02-29 )
Nächstes Ertragsdatum	( $-0.690 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.65
ATR14	$0.0450 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	Von Seggern Christopher	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Aulin Sherry	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Kenney Christopher John	Buy	100 000	Stock Option (Right to Buy)
2024-03-11	Empfield James R.	Buy	65 000	Stock Option (Right to Buy)
2024-03-11	Robin Sherrington	Buy	65 000	Stock Option (Right to Buy)

INSIDER POWER
59.32
Last 100 transactions
Buy: 2 181 840 \| Sell: 619 411

Volumen Korrelation

Lang: 0.19 (neutral)

Kurz: -0.17 (neutral)

Signal:(67.89) Neutral

Xenon Pharmaceuticals Inc Korrelation

10 Am meisten positiv korreliert
PAIC	0.905
SVAC	0.827
GOODM	0.825
TLGT	0.818

10 Am meisten negativ korreliert
RAVN	-0.9
NETE	-0.871
BOCH	-0.849
MMAC	-0.824
SHSP	-0.824
AMRB	-0.807

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Xenon Pharmaceuticals Inc Korrelation - Währung/Rohstoff

-0.65
( moderate negative )

-0.65
( weak negative )

0.00
( neutral )

-0.54
( weak negative )

0.69
( moderate )

0.47
( neutral )

Xenon Pharmaceuticals Inc Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2023
Umsatz:	$0
Bruttogewinn:	$-3.54M (0.00 %)
EPS:	$-2.73

FY	2022
Umsatz:	$9.43M
Bruttogewinn:	$-96.33M (-1 021.13 %)
EPS:	$-2.07

FY	2021
Umsatz:	$18.44M
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.